BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: de Wolf C, van de Bovenkamp M, Hoefnagel M. Regulatory perspective on in vitro potency assays for human mesenchymal stromal cells used in immunotherapy. Cytotherapy 2017;19:784-97. [PMID: 28457740 DOI: 10.1016/j.jcyt.2017.03.076] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 9.6] [Reference Citation Analysis]
Number Citing Articles
1 Bahsoun S, Coopman K, Akam EC. The impact of cryopreservation on bone marrow-derived mesenchymal stem cells: a systematic review. J Transl Med 2019;17:397. [PMID: 31783866 DOI: 10.1186/s12967-019-02136-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
2 Lechanteur C, Briquet A, Bettonville V, Baudoux E, Beguin Y. MSC Manufacturing for Academic Clinical Trials: From a Clinical-Grade to a Full GMP-Compliant Process. Cells 2021;10:1320. [PMID: 34073206 DOI: 10.3390/cells10061320] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Maumus M, Pers YM, Ruiz M, Jorgensen C, Noël D. [Mesenchymal stem cells and regenerative medicine: future perspectives in osteoarthritis]. Med Sci (Paris) 2018;34:1092-9. [PMID: 30623767 DOI: 10.1051/medsci/2018294] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
4 Garcia-Arranz M, Garcia-Olmo D, Herreros MD, Gracia-Solana J, Guadalajara H, de la Portilla F, Baixauli J, Garcia-Garcia J, Ramirez JM, Sanchez-Guijo F, Prosper F;  FISPAC Collaborative Group. Autologous adipose-derived stem cells for the treatment of complex cryptoglandular perianal fistula: A randomized clinical trial with long-term follow-up. Stem Cells Transl Med. 2020;9:295-301. [PMID: 31886629 DOI: 10.1002/sctm.19-0271] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
5 Shaw TD, Krasnodembskaya AD, Schroeder GN, Zumla A, Maeurer M, O'Kane CM. Mesenchymal Stromal Cells: an Antimicrobial and Host-Directed Therapy for Complex Infectious Diseases. Clin Microbiol Rev 2021;:e0006421. [PMID: 34612662 DOI: 10.1128/CMR.00064-21] [Reference Citation Analysis]
6 Serra M, Cunha B, Peixoto C, Gomes-alves P, Alves PM. Advancing manufacture of human mesenchymal stem cells therapies: technological challenges in cell bioprocessing and characterization. Current Opinion in Chemical Engineering 2018;22:226-35. [DOI: 10.1016/j.coche.2018.11.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
7 Robb KP, Fitzgerald JC, Barry F, Viswanathan S. Mesenchymal stromal cell therapy: progress in manufacturing and assessments of potency. Cytotherapy. 2019;21:289-306. [PMID: 30528726 DOI: 10.1016/j.jcyt.2018.10.014] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 10.3] [Reference Citation Analysis]
8 Kandoi S, L PK, Patra B, Vidyasekar P, Sivanesan D, S V, K R, Verma RS. Evaluation of platelet lysate as a substitute for FBS in explant and enzymatic isolation methods of human umbilical cord MSCs. Sci Rep. 2018;8:12439. [PMID: 30127445 DOI: 10.1038/s41598-018-30772-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
9 Marcheque J, Bussolati B, Csete M, Perin L. Concise Reviews: Stem Cells and Kidney Regeneration: An Update. Stem Cells Transl Med 2019;8:82-92. [PMID: 30302937 DOI: 10.1002/sctm.18-0115] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
10 Maughon TS, Shen X, Huang D, Michael AOA, Shockey WA, Andrews SH, McRae JM 3rd, Platt MO, Fernández FM, Edison AS, Stice SL, Marklein RA. Metabolomics and cytokine profiling of mesenchymal stromal cells identify markers predictive of T-cell suppression. Cytotherapy 2021:S1465-3249(21)00775-1. [PMID: 34696960 DOI: 10.1016/j.jcyt.2021.08.002] [Reference Citation Analysis]
11 Mosallaei M, Simonian M, Ehtesham N, Karimzadeh MR, Vatandoost N, Negahdari B, Salehi R. Genetically engineered mesenchymal stem cells: targeted delivery of immunomodulatory agents for tumor eradication. Cancer Gene Ther 2020;27:854-68. [PMID: 32418986 DOI: 10.1038/s41417-020-0179-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Viganò M, Budelli S, Lavazza C, Montemurro T, Montelatici E, de Cesare S, Lazzari L, Orlandi AR, Lunghi G, Giordano R. Tips and Tricks for Validation of Quality Control Analytical Methods in Good Manufacturing Practice Mesenchymal Stromal Cell Production. Stem Cells Int 2018;2018:3038565. [PMID: 30254681 DOI: 10.1155/2018/3038565] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
13 Salvadori M, Cesari N, Murgia A, Puccini P, Riccardi B, Dominici M. Dissecting the Pharmacodynamics and Pharmacokinetics of MSCs to Overcome Limitations in Their Clinical Translation. Mol Ther Methods Clin Dev 2019;14:1-15. [PMID: 31236426 DOI: 10.1016/j.omtm.2019.05.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
14 Wiese DM, Wood CA, Braid LR. From Vial to Vein: Crucial Gaps in Mesenchymal Stromal Cell Clinical Trial Reporting. Front Cell Dev Biol 2022;10:867426. [DOI: 10.3389/fcell.2022.867426] [Reference Citation Analysis]
15 Brandão JS, Alvarenga ML, Pfeifer JPH, dos Santos VH, Fonseca-alves CE, Rodrigues M, Laufer-amorim R, Castillo JAL, Alves ALG. Allogeneic mesenchymal stem cell transplantation in healthy equine superficial digital flexor tendon: A study of the local inflammatory response. Research in Veterinary Science 2018;118:423-30. [DOI: 10.1016/j.rvsc.2018.03.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
16 Floy ME, Mateyka TD, Foreman KL, Palecek SP. Human pluripotent stem cell-derived cardiac stromal cells and their applications in regenerative medicine. Stem Cell Res 2020;45:101831. [PMID: 32446219 DOI: 10.1016/j.scr.2020.101831] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
17 Blanco-Fernandez B, Cano-Torres I, Garrido C, Rubi-Sans G, Sanchez-Cid L, Guerra-Rebollo M, Rubio N, Blanco J, Perez-Amodio S, Mateos-Timoneda MA, Engel E. Engineered microtissues for the bystander therapy against cancer. Mater Sci Eng C Mater Biol Appl 2021;121:111854. [PMID: 33579487 DOI: 10.1016/j.msec.2020.111854] [Reference Citation Analysis]
18 Wong SW, Lenzini S, Giovanni R, Knowles K, Shin JW. Matrix biophysical cues direct mesenchymal stromal cell functions in immunity. Acta Biomater 2021:S1742-7061(21)00513-4. [PMID: 34365041 DOI: 10.1016/j.actbio.2021.07.075] [Reference Citation Analysis]
19 Khong D, Li M, Singleton A, Chin LY, Mukundan S, Parekkadan B. Orthogonal potency analysis of mesenchymal stromal cell function during ex vivo expansion. Exp Cell Res 2018;362:102-10. [PMID: 29137914 DOI: 10.1016/j.yexcr.2017.11.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
20 Levy O, Kuai R, Siren EMJ, Bhere D, Milton Y, Nissar N, De Biasio M, Heinelt M, Reeve B, Abdi R, Alturki M, Fallatah M, Almalik A, Alhasan AH, Shah K, Karp JM. Shattering barriers toward clinically meaningful MSC therapies. Sci Adv 2020;6:eaba6884. [PMID: 32832666 DOI: 10.1126/sciadv.aba6884] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 29.0] [Reference Citation Analysis]
21 Ragni E, Papait A, Perucca Orfei C, Silini AR, Colombini A, Viganò M, Libonati F, Parolini O, de Girolamo L. Amniotic membrane-mesenchymal stromal cells secreted factors and extracellular vesicle-miRNAs: Anti-inflammatory and regenerative features for musculoskeletal tissues. Stem Cells Transl Med 2021;10:1044-62. [PMID: 33656805 DOI: 10.1002/sctm.20-0390] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
22 Cheng F, Huang Z, Li Z. Efficacy and Safety of Mesenchymal Stem Cells in Treatment of Complex Perianal Fistulas: A Meta-Analysis. Stem Cells Int 2020;2020:8816737. [PMID: 33299423 DOI: 10.1155/2020/8816737] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Andrews SH, Klinker MW, Bauer SR, Marklein RA. Morphological landscapes from high content imaging reveal cytokine priming strategies that enhance mesenchymal stromal cell immunosuppression. Biotechnol Bioeng 2021. [PMID: 34716713 DOI: 10.1002/bit.27974] [Reference Citation Analysis]
24 Mebarki M, Iglicki N, Marigny C, Abadie C, Nicolet C, Churlaud G, Maheux C, Boucher H, Monsel A, Menasché P, Larghero J, Faivre L, Cras A. Development of a human umbilical cord-derived mesenchymal stromal cell-based advanced therapy medicinal product to treat immune and/or inflammatory diseases. Stem Cell Res Ther 2021;12:571. [PMID: 34774107 DOI: 10.1186/s13287-021-02637-7] [Reference Citation Analysis]
25 Carreras-Sánchez I, López-Fernández A, Rojas-Márquez R, Vélez R, Aguirre M, Vives J. Derivation of Mesenchymal Stromal Cells from Ovine Umbilical Cord Wharton's Jelly. Curr Protoc 2021;1:e18. [PMID: 33484488 DOI: 10.1002/cpz1.18] [Reference Citation Analysis]
26 Seo Y, Kang MJ, Kim HS. Strategies to Potentiate Paracrine Therapeutic Efficacy of Mesenchymal Stem Cells in Inflammatory Diseases. Int J Mol Sci 2021;22:3397. [PMID: 33806241 DOI: 10.3390/ijms22073397] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
27 Machiesky L, Côté O, Kirkegaard LH, Mefferd SC, Larkin C. A rapid lateral flow immunoassay for identity testing of biotherapeutics. Journal of Immunological Methods 2019;474:112666. [DOI: 10.1016/j.jim.2019.112666] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
28 Wright A, Arthaud-Day ML, Weiss ML. Therapeutic Use of Mesenchymal Stromal Cells: The Need for Inclusive Characterization Guidelines to Accommodate All Tissue Sources and Species. Front Cell Dev Biol 2021;9:632717. [PMID: 33665190 DOI: 10.3389/fcell.2021.632717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
29 Wilson A, Webster A, Genever P. Nomenclature and heterogeneity: consequences for the use of mesenchymal stem cells in regenerative medicine. Regen Med 2019;14:595-611. [PMID: 31115266 DOI: 10.2217/rme-2018-0145] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
30 Chinnadurai R, Rajan D, Qayed M, Arafat D, Garcia M, Liu Y, Kugathasan S, Anderson LJ, Gibson G, Galipeau J. Potency Analysis of Mesenchymal Stromal Cells Using a Combinatorial Assay Matrix Approach. Cell Rep 2018;22:2504-17. [PMID: 29490284 DOI: 10.1016/j.celrep.2018.02.013] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 22.3] [Reference Citation Analysis]
31 van Rhijn-Brouwer FCC, Gremmels H, Fledderus JO, Verhaar MC. Mesenchymal Stromal Cell Characteristics and Regenerative Potential in Cardiovascular Disease: Implications for Cellular Therapy. Cell Transplant 2018;27:765-85. [PMID: 29895169 DOI: 10.1177/0963689717738257] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
32 DE Wolf C, VAN DE Bovenkamp M, Hoefnagel M. Regulatory perspective on in vitro potency assays for human dendritic cells used in anti-tumor immunotherapy. Cytotherapy 2018;20:1289-308. [PMID: 30327247 DOI: 10.1016/j.jcyt.2018.07.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
33 Mehler VJ, Burns C, Moore ML. Concise Review: Exploring Immunomodulatory Features of Mesenchymal Stromal Cells in Humanized Mouse Models. Stem Cells 2019;37:298-305. [PMID: 30395373 DOI: 10.1002/stem.2948] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
34 Ramallo M, Carreras-Sánchez I, López-Fernández A, Vélez R, Aguirre M, Feldman S, Vives J. Advances in translational orthopaedic research with species-specific multipotent mesenchymal stromal cells derived from the umbilical cord. Histol Histopathol 2021;36:19-30. [PMID: 32914860 DOI: 10.14670/HH-18-249] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Galganski LA, Kumar P, Vanover MA, Pivetti CD, Anderson JE, Lankford L, Paxton ZJ, Chung K, Lee C, Hegazi MS, Yamashiro KJ, Wang A, Farmer DL. In utero treatment of myelomeningocele with placental mesenchymal stromal cells - Selection of an optimal cell line in preparation for clinical trials. J Pediatr Surg 2020;55:1941-6. [PMID: 31672407 DOI: 10.1016/j.jpedsurg.2019.09.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
36 Williams EK, García JR, Mannino RG, Schneider RS, Lam WA, García AJ. Enabling mesenchymal stromal cell immunomodulatory analysis using scalable platforms. Integr Biol (Camb) 2019;11:154-62. [PMID: 31135880 DOI: 10.1093/intbio/zyz014] [Reference Citation Analysis]
37 Oliver-Vila I, Ramírez-Moncayo C, Grau-Vorster M, Marín-Gallén S, Caminal M, Vives J. Optimisation of a potency assay for the assessment of immunomodulative potential of clinical grade multipotent mesenchymal stromal cells. Cytotechnology 2018;70:31-44. [PMID: 29322348 DOI: 10.1007/s10616-017-0186-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
38 Mu Y, Wu X, Hao Z. Comparative evaluation of mesenchymal stromal cells from umbilical cord and amniotic membrane in xeno-free conditions. BMC Cell Biol 2018;19:27. [PMID: 30545286 DOI: 10.1186/s12860-018-0178-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
39 Bieback K, Kuçi S, Schäfer R. Production and quality testing of multipotent mesenchymal stromal cell therapeutics for clinical use. Transfusion 2019. [DOI: 10.1111/trf.15252] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
40 Vives J, Mirabel C. Multipotent Mesenchymal Stromal Cells From Bone Marrow for Current and Potential Clinical Applications. Reference Module in Biomedical Sciences. Elsevier; 2018. [DOI: 10.1016/b978-0-12-801238-3.65506-x] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
41 Chen HH, Chen YC, Yu SN, Lai WL, Shen YS, Shen PC, Lin SH, Chang CH, Lee SM. Infrapatellar fat pad-derived mesenchymal stromal cell product for treatment of knee osteoarthritis: a first-in-human study with evaluation of the potency marker. Cytotherapy 2021;:1377. [PMID: 34696962 DOI: 10.1016/j.jcyt.2021.08.006] [Reference Citation Analysis]
42 Cerignoli F, Abassi YA, Lamarche BJ, Guenther G, Santa Ana D, Guimet D, Zhang W, Zhang J, Xi B. In vitro immunotherapy potency assays using real-time cell analysis. PLoS One 2018;13:e0193498. [PMID: 29499048 DOI: 10.1371/journal.pone.0193498] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
43 Guerrouahen BS, Sidahmed H, Al Sulaiti A, Al Khulaifi M, Cugno C. Enhancing Mesenchymal Stromal Cell Immunomodulation for Treating Conditions Influenced by the Immune System. Stem Cells Int. 2019;2019:7219297. [PMID: 31467564 DOI: 10.1155/2019/7219297] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
44 Tavridou A, Rogers D, Bonelli M, Schiel A, Hidalgo-Simon A. Towards a better use of scientific advice for developers of advanced therapies. Br J Clin Pharmacol 2021;87:2459-64. [PMID: 33237580 DOI: 10.1111/bcp.14672] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
45 Marklein RA, Klinker MW, Drake KA, Polikowsky HG, Lessey-Morillon EC, Bauer SR. Morphological profiling using machine learning reveals emergent subpopulations of interferon-γ-stimulated mesenchymal stromal cells that predict immunosuppression. Cytotherapy 2019;21:17-31. [PMID: 30503100 DOI: 10.1016/j.jcyt.2018.10.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
46 Guan Q, Li Y, Shpiruk T, Bhagwat S, Wall DA. Inducible indoleamine 2,3-dioxygenase 1 and programmed death ligand 1 expression as the potency marker for mesenchymal stromal cells. Cytotherapy 2018;20:639-49. [PMID: 29548707 DOI: 10.1016/j.jcyt.2018.02.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
47 Zavala G, Ramos MP, Figueroa-Valdés AI, Cisternas P, Wyneken U, Hernández M, Toa P, Salmons B, Dangerfield J, Gunzburg WH, Khoury M. Semipermeable Cellulose Beads Allow Selective and Continuous Release of Small Extracellular Vesicles (sEV) From Encapsulated Cells. Front Pharmacol 2020;11:679. [PMID: 32528280 DOI: 10.3389/fphar.2020.00679] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
48 Guadix JA, López-Beas J, Clares B, Soriano-Ruiz JL, Zugaza JL, Gálvez-Martín P. Principal Criteria for Evaluating the Quality, Safety and Efficacy of hMSC-Based Products in Clinical Practice: Current Approaches and Challenges. Pharmaceutics 2019;11:E552. [PMID: 31652984 DOI: 10.3390/pharmaceutics11110552] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
49 Wruck W, Graffmann N, Spitzhorn LS, Adjaye J. Human Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells Acquire Rejuvenation and Reduced Heterogeneity. Front Cell Dev Biol 2021;9:717772. [PMID: 34604216 DOI: 10.3389/fcell.2021.717772] [Reference Citation Analysis]
50 Dovgan B, Miklavčič D, Knežević M, Zupan J, Barlič A. Intracellular delivery of trehalose renders mesenchymal stromal cells viable and immunomodulatory competent after cryopreservation. Cytotechnology 2021;:1-21. [PMID: 33875905 DOI: 10.1007/s10616-021-00465-4] [Reference Citation Analysis]
51 Nicotra T, Desnos A, Halimi J, Antonot H, Reppel L, Belmas T, Freton A, Stranieri F, Mebarki M, Larghero J, Cras A, Faivre L. Mesenchymal stem/stromal cell quality control: validation of mixed lymphocyte reaction assay using flow cytometry according to ICH Q2(R1). Stem Cell Res Ther 2020;11:426. [PMID: 33004063 DOI: 10.1186/s13287-020-01947-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]